GlassScriptPhysician profile
Manoj Makhija
NPI 1588657365
$5,891.73
in general payments reported to CMS, 2019-2025
54 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $811 · 2021: $1,147 · 2022: $1,035 · 2023: $960 · 2024: $574 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,894.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,094.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $615.99 | 2019-2023 | Ofev |
| Mylan Specialty L.P. | $487.55 | 2020-2023 | Yupelri |
| Electromed, INC. | $276.59 | 2019-2024 | Smartvest |
| Amgen INC. | $259.73 | 2019-2024 | Repatha, Tezspire, Prolia |
| Actelion Pharmaceuticals US, INC. | $249.68 | 2019-2023 | Opsumit, Uptravi |
| United Therapeutics Corporation | $236.08 | 2019-2023 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $224.17 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $214.73 | 2020-2023 | Glassia |
| Abbvie INC. | $189.96 | 2021-2025 | |
| Astellas Pharma US INC | $186.63 | 2019-2024 | Veozah |
| Regeneron Healthcare Solutions, INC. | $155.04 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $133.68 | 2021-2022 | |
| Abbott Laboratories | $116.25 | 2021-2025 | Eterna, Assurity, Proclaim |
| Pfizer INC. | $109.45 | 2019-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Makhija listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.